Clinical Trials Browser

INDUSTRY × Head and Neck Neoplasms × Afatinib × Clear all

NCT01856478 2026-01-12

LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Phase 3 Completed

340 enrolled 23 charts

Head and Neck Neoplasms

NCT02131155 2019-03-01

LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

Phase 3 Terminated

36 enrolled 6 charts

Head and Neck Neoplasms

NCT01345682 2018-02-15

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Phase 3 Completed

483 enrolled 21 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT01345669 2017-12-07

LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

Phase 3 Terminated

617 enrolled 13 charts

Head and Neck Neoplasms

NCT00514943 2016-07-26

BIBW 2992 (Afatinib) in Head & Neck Cancer

Phase 2 Completed

124 enrolled 31 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms